P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis
- PMID: 25337256
- PMCID: PMC4203227
P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis
Abstract
Osteosarcoma is one of the most common primary bone malignancies. Although there is a significant improvement of survival on osteosarcoma patients in the past decades, treatment of osteosarcoma is still unsatisfactory for the development of pulmonary metastasis. The potential prognostic value of p16(INK4a) in osteosarcoma has been investigated, however, the results from different studies were somewhat controversial. To elucidate whether p16(INK4a) is indeed a prognostic factor of osteosarcoma, we conducted a meta-analysis of the published literatures to provide a comprehensive evaluation of the significance of p16(INK4a) expression in patients with osteosarcoma. Eight studies with a total of 354 patients with osteosarcoma were examined. The pooled odds ratio (OR) with corresponding 95% confidence interval (95% CI) was calculated to evaluate the effect of p16(INK4a) expression on overall survival. Meta-analysis showed that patients with high p16(INK4a) expression were significantly associated with favourable overall survival when compared to their counterparts with low or undetectable p16(INK4a) expression (OR = 0.270, 95% CI 0.162-0.451, P < 0.001). Sensitivity analysis suggested the pooled OR was stable and not significantly changed when a single study was removed. In conclusion, the results from this meta-analysis highlight that p16(INK4a) is an effective biomarker of survival in patients with osteosarcoma.
Keywords: Osteosarcoma P16INK4a expression; meta-analysis; survival.
Figures
Comment in
-
Comments on the article of Bu, et al entitled "P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis".Int J Clin Exp Pathol. 2015 Mar 1;8(3):3384-5. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26045875 Free PMC article. No abstract available.
-
Comments on Bu et al. "P16(INK₄a) overexpression and survival in osteosarcoma patients: a meta analysis".Int J Clin Exp Pathol. 2015 Jun 1;8(6):7617-8. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26261680 Free PMC article.
Similar articles
-
Comments on Bu et al. "P16(INK₄a) overexpression and survival in osteosarcoma patients: a meta analysis".Int J Clin Exp Pathol. 2015 Jun 1;8(6):7617-8. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26261680 Free PMC article.
-
P16 protein expression as a useful predictive biomarker for neoadjuvant chemotherapy response in patients with high-grade osteosarcoma: A systematic meta-analysis under guideline of PRISMA.Medicine (Baltimore). 2017 May;96(19):e6714. doi: 10.1097/MD.0000000000006714. Medicine (Baltimore). 2017. PMID: 28489748 Free PMC article. Review.
-
p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases.Hum Pathol. 2016 Dec;58:15-23. doi: 10.1016/j.humpath.2016.07.023. Epub 2016 Aug 18. Hum Pathol. 2016. PMID: 27544803
-
Comments on the article of Bu, et al entitled "P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis".Int J Clin Exp Pathol. 2015 Mar 1;8(3):3384-5. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26045875 Free PMC article. No abstract available.
-
Prognostic value of p53 alterations in human osteosarcoma: a meta analysis.Int J Clin Exp Pathol. 2014 Sep 15;7(10):6725-33. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25400752 Free PMC article. Review.
Cited by
-
Comments on Bu et al. "P16(INK₄a) overexpression and survival in osteosarcoma patients: a meta analysis".Int J Clin Exp Pathol. 2015 Jun 1;8(6):7617-8. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26261680 Free PMC article.
-
p16INK4a inhibits the proliferation of osteosarcoma cells through regulating the miR-146b-5p/TRAF6 pathway.Biosci Rep. 2019 Feb 1;39(2):BSR20181268. doi: 10.1042/BSR20181268. Print 2019 Feb 28. Biosci Rep. 2019. PMID: 30643010 Free PMC article.
-
Prognostic Value of Overexpressed p16INK4a in Vulvar Cancer: A Meta-Analysis.PLoS One. 2016 Mar 31;11(3):e0152459. doi: 10.1371/journal.pone.0152459. eCollection 2016. PLoS One. 2016. PMID: 27031618 Free PMC article.
-
P16 protein expression as a useful predictive biomarker for neoadjuvant chemotherapy response in patients with high-grade osteosarcoma: A systematic meta-analysis under guideline of PRISMA.Medicine (Baltimore). 2017 May;96(19):e6714. doi: 10.1097/MD.0000000000006714. Medicine (Baltimore). 2017. PMID: 28489748 Free PMC article. Review.
-
A Study of Prognostic Factors in Young Patients With Non-HPV Oral Cancer in Central Europe.Pathol Oncol Res. 2021 Dec 22;27:1609991. doi: 10.3389/pore.2021.1609991. eCollection 2021. Pathol Oncol Res. 2021. PMID: 35002542 Free PMC article.
References
-
- Miao J, Wu S, Peng Z, Tania M, Zhang C. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol. 2013;34:2093–2098. - PubMed
-
- Hameed M, Dorfman H. Primary malignant bone tumors--recent developments. Semin Diagn Pathol. 2011;28:86–101. - PubMed
-
- Zou C, Shen J, Tang Q, Yang Z, Yin J, Li Z, Xie X, Huang G, Lev D, Wang J. Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis. Cancer. 2012;118:1845–1855. - PubMed
-
- Knosel T, Altendorf-Hofmann A, Lindner L, Issels R, Hermeking H, Schuebbe G, Gibis S, Siemens H, Kampmann E, Kirchner T. Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier. J Clin Pathol. 2014;67:592–598. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous